90 related articles for article (PubMed ID: 37221610)
21. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
[TBL] [Abstract][Full Text] [Related]
22. Tumor-to-tumor metastases: papillary thyroid carcinoma into a clear cell renal cell carcinoma.
Song JS; Taylor SM; Trites J; Rigby MH; Bullock MJ; Merrimen J; Rendon R; Hart RD
J Otolaryngol Head Neck Surg; 2017 Mar; 46(1):17. PubMed ID: 28249616
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
24. BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review.
A Al Hamad M; Albisher HM; Al Saeed WR; Almumtin AT; Allabbad FM; A Shawarby M
BMC Cancer; 2019 Feb; 19(1):170. PubMed ID: 30795755
[TBL] [Abstract][Full Text] [Related]
25. Tumor Cell-Derived Exosomal circ-PRKCI Promotes Proliferation of Renal Cell Carcinoma via Regulating miR-545-3p/CCND1 Axis.
Qian Y; Li Y; Xu L; Chen K; Liu N; Yang X; Lv Q; Li R; Zhou C; Xu Z; Jia R; Ge YZ
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612120
[TBL] [Abstract][Full Text] [Related]
26. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.
Li Q; Li Z; Luo T; Shi H
Mol Biomed; 2022 Dec; 3(1):47. PubMed ID: 36539659
[TBL] [Abstract][Full Text] [Related]
27. New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking.
Zerfaoui M; Dokunmu TM; Toraih EA; Rezk BM; Abd Elmageed ZY; Kandil E
Cells; 2021 Feb; 10(2):. PubMed ID: 33578751
[TBL] [Abstract][Full Text] [Related]
28. Melanoma and Thyroid Carcinoma: Our Current Understanding.
Lazzara DR; Zarkhin SG; Rubenstein SN; Glick BP
J Clin Aesthet Dermatol; 2019 Sep; 12(9):39-41. PubMed ID: 31641417
[TBL] [Abstract][Full Text] [Related]
29. Multiple primary tumours: challenges and approaches, a review.
Vogt A; Schmid S; Heinimann K; Frick H; Herrmann C; Cerny T; Omlin A
ESMO Open; 2017; 2(2):e000172. PubMed ID: 28761745
[TBL] [Abstract][Full Text] [Related]
30. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.
Cicenas J; Tamosaitis L; Kvederaviciute K; Tarvydas R; Staniute G; Kalyan K; Meskinyte-Kausiliene E; Stankevicius V; Valius M
Med Oncol; 2017 Feb; 34(2):26. PubMed ID: 28074351
[TBL] [Abstract][Full Text] [Related]
31. Cyclin D1, cancer progression, and opportunities in cancer treatment.
Qie S; Diehl JA
J Mol Med (Berl); 2016 Dec; 94(12):1313-1326. PubMed ID: 27695879
[TBL] [Abstract][Full Text] [Related]
32. Microsatellite instability in melanoma: a comprehensive review.
Kubeček O; Kopecký J
Melanoma Res; 2016 Dec; 26(6):545-550. PubMed ID: 27623135
[TBL] [Abstract][Full Text] [Related]
33. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome.
Tavares C; Melo M; Cameselle-Teijeiro JM; Soares P; Sobrinho-Simões M
Eur J Endocrinol; 2016 Apr; 174(4):R117-26. PubMed ID: 26510840
[TBL] [Abstract][Full Text] [Related]
34. Functional TSH Receptors, Malignant Melanomas and Subclinical Hypothyroidism.
Ursu HI
Eur Thyroid J; 2012 Oct; 1(3):208. PubMed ID: 24783022
[No Abstract] [Full Text] [Related]
35. Increased melanoma risk in individuals with papillary thyroid carcinoma.
Oakley GM; Curtin K; Layfield L; Jarboe E; Buchmann LO; Hunt JP
JAMA Otolaryngol Head Neck Surg; 2014 May; 140(5):423-7. PubMed ID: 24626334
[TBL] [Abstract][Full Text] [Related]
36. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.
Bertolotto C; Lesueur F; Giuliano S; Strub T; de Lichy M; Bille K; Dessen P; d'Hayer B; Mohamdi H; Remenieras A; Maubec E; de la Fouchardière A; Molinié V; Vabres P; Dalle S; Poulalhon N; Martin-Denavit T; Thomas L; Andry-Benzaquen P; Dupin N; Boitier F; Rossi A; Perrot JL; Labeille B; Robert C; Escudier B; Caron O; Brugières L; Saule S; Gardie B; Gad S; Richard S; Couturier J; Teh BT; Ghiorzo P; Pastorino L; Puig S; Badenas C; Olsson H; Ingvar C; Rouleau E; Lidereau R; Bahadoran P; Vielh P; Corda E; Blanché H; Zelenika D; Galan P; ; Aubin F; Bachollet B; Becuwe C; Berthet P; Bignon YJ; Bonadona V; Bonafe JL; Bonnet-Dupeyron MN; Cambazard F; Chevrant-Breton J; Coupier I; Dalac S; Demange L; d'Incan M; Dugast C; Faivre L; Vincent-Fétita L; Gauthier-Villars M; Gilbert B; Grange F; Grob JJ; Humbert P; Janin N; Joly P; Kerob D; Lasset C; Leroux D; Levang J; Limacher JM; Livideanu C; Longy M; Lortholary A; Stoppa-Lyonnet D; Mansard S; Mansuy L; Marrou K; Matéus C; Maugard C; Meyer N; Nogues C; Souteyrand P; Venat-Bouvet L; Zattara H; Chaudru V; Lenoir GM; Lathrop M; Davidson I; Avril MF; Demenais F; Ballotti R; Bressac-de Paillerets B
Nature; 2011 Oct; 480(7375):94-8. PubMed ID: 22012259
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of the coexistence of melanoma and renal cell carcinoma.
Maubec E; Chaudru V; Mohamdi H; Grange F; Patard JJ; Dalle S; Crickx B; Paillerets BB; Demenais F; Avril MF
Cancer; 2010 Dec; 116(24):5716-24. PubMed ID: 21218461
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous malignant melanoma associated with papillary thyroid cancer.
Kim CY; Lee SH; Oh CW
Ann Dermatol; 2010 Aug; 22(3):370-2. PubMed ID: 20711283
[TBL] [Abstract][Full Text] [Related]
39. The genetic basis of kidney cancer: a metabolic disease.
Linehan WM; Srinivasan R; Schmidt LS
Nat Rev Urol; 2010 May; 7(5):277-85. PubMed ID: 20448661
[TBL] [Abstract][Full Text] [Related]
40. Fifteen-year quest for microphthalmia-associated transcription factor target genes.
Cheli Y; Ohanna M; Ballotti R; Bertolotto C
Pigment Cell Melanoma Res; 2010 Feb; 23(1):27-40. PubMed ID: 19995375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
